• Home
  • Science
  • Therapeutic Strategy
  • dry AMD
  • Pipeline
  • Team
  • Contact Us
  • Publications
  • More
    • Home
    • Science
    • Therapeutic Strategy
    • dry AMD
    • Pipeline
    • Team
    • Contact Us
    • Publications
  • Home
  • Science
  • Therapeutic Strategy
  • dry AMD
  • Pipeline
  • Team
  • Contact Us
  • Publications
Artistic interpretation of the visual process
PROJECT VISIONS (www.the-visions.com)

Therapeutics for Macular Degeneration and Other Age-Related Disorders

Visgenx is developing therapeutics based on increasing  expression of a gene known as ELOVL2  which has been shown to regulate aging in the retina and other tissues

THERAPEUTIC STRATEGY

Increase expression of ELOVL2 by: 1) Epigenetic rescue  and 2) ELOVL2 gene therapy

 


LEAD INDICATION

Age-related Macular Degeneration / Geographic Atrophy 

Find out more

Copyright © 2020 Visgenx, Inc. - All Rights Reserved.

Powered by GoDaddy